Some of the world's largest hedge funds are hiring doctors, scientists and analysts to give them expert insight into the ...

Bristol Myers Squibb Co. closed $2.39 below its 52-week high ($61.08), which the company reached on November 11th.

Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

This year has seen sharp stock moves as companies report financial results and update investors on early and mid-stage drug studies ...

RWJBarnabas Health appoints Steven Stylianos, MD as system director for pediatric surgery and surgeon-in-chief at Bristol-Myers Squibb Children's Hospital ...

Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for ...